Celleron Therapeutics announces MHRA Clinical Trial Authorisation for CXD101 in Microsatellite-Stable Colorectal Cancer
UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.
Category Press Releases
Celleron Therapeutics appoints Bill Fleming as its Chief Financial Officer
Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Bill Fleming as its Chief Financial Officer. This appointment represents an important milestone for the company…
Celleron Therapeutics announces EMA COMP Orphan Drug designation for CXD101 in peripheral T-cell lymphoma
Oxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the grant of EU Orphan Drug Designation for Celleron’s lead compound CXD101 for peripheral T-cell lymphoma. On 8 November, 2017…
Celleron Therapeutics announces Licensing and Co-Development Agreement with Nuance Biotech for China and South Africa
Oxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that it has signed Licensing and Co-development agreements for China and South Africa with Nuance Biotech, the Shanghai based…
Dr Chris Towler joins the Board of Celleron Therapeutics
Oxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that Dr Chris Towler is joining the Board of Directors as an Observer, appointed by the University of Oxford.…
CXD101 presented at 3rd Shanghai International Forum
Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the 3rd Shanghai International Forum for…
Dr. Doug Manion joins Board of Celleron Therapeutics
Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that Doug Manion M.D., FRCP(C) is joining the Board of Directors as a Non Executive Director, with immediate effect.…
CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research
Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the Inaugural Meeting of the…
Celleron Therapeutics announces completion of a new funding round with international investors
Oxford 31st January 2017; Celleron Therapeutics Limited, the UK-based precision cancer medicines company, focussed on clinical trials of novel small molecule therapeutics, announced today that it has completed a new financing round with a consortium of South Korean investors. Celleron…
Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients
Oxford, UK, 1st December 2015; Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced that significant clinical activity was observed in the first human trial of its pioneering personalised cancer treatment CXD101 in patients at…